Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07648758 · ClinicalTrials.gov registry record · NA

Produce Prescription for Healthy Blood Pressure

A NA study, sponsored by Texas A&M University.

Completed
Registry status
NA
Development phase
104
Enrollment target

NCT07648758: Completed NA study, sponsored by Texas A&M University.

NCT07648758 is a NA study that has completed, run by Texas A&M University. The registered enrollment target is 104 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07648758, a NA study, has completed, sponsored by Texas A&M University.

COMPLETED
Registry status
NA
Development phase
104 participants
Enrollment target

Study Summary

The investigators want to understand the effects of the Produce Prescription for Healthy Blood Pressure program on blood pressure control and people's health. The overall project goal is to improve blood pressure levels of West Dallas residents with high blood pressure through participation in this produce prescription program.

Primary Outcome

Blood pressure will be measured at baseline (pre-intervention; prior to commencement of PRxBP program for intervention group) and endpoint (post-intervention; after PRx BP program ends for intervention group), measured in triplicate (both measured as mmHg) using best-practice research standards with the clinically validated Omron IntelliSense Professional Blood Pressure Monitor.

Interventions

  • BEHAVIORAL Produce Prescription for Healthy Blood Pressure (PRx-BP) program

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2023-05-05
Est. Completion 2024-07-01
Phase NA
Texas A&M University

95 total trials

What the finished NCT07648758 record still lists

NCT07648758 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 1 intervention - of which Produce Prescription for Healthy Blood Pressure (PRx-BP) program is the first listed.

NCT07648758 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07648758 about?

NCT07648758 is a clinical study titled "Produce Prescription for Healthy Blood Pressure". The investigators want to understand the effects of the Produce Prescription for Healthy Blood Pressure program on blood pressure control and people's health. The overall project goal is to improve blood pressure levels of West Dallas residents with high blood pressure through participation in this ...

What is the current status of trial NCT07648758?

This trial is currently completed. It is a NA study. The enrollment target is 104 participants. The study started on 2023-05-05. Estimated completion is 2024-07-01.

What interventions are being tested in trial NCT07648758?

The interventions under investigation include: Produce Prescription for Healthy Blood Pressure (PRx-BP) program (BEHAVIORAL).

Who is sponsoring clinical trial NCT07648758?

This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07648758's enrollment target sits among peer trials

104 836th of 2000 higher than 1,164 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03403686 · 104 participants

    Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

  • NCT04228367 · 104 participants · NA

    JuggerStitch Post Market Clinical Follow-up Study

  • NCT04268849 · 104 participants · Phase 3

    Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

  • NCT04390724 · 104 participants

    Optimizing Y90 Therapy for Radiation Lobectomy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07648758, the US trial registry maintained by the National Library of Medicine. NCT07648758 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.